The ability of insulin to mediate glucose disposal varies more than six-fold in an apparently healthy population, and approximately one third of the most insulin-resistant of these individuals are at increased risk to develop cardiovascular disease. Differences in degree of adiposity account for approximately 25% of this variability, and another 25% varies as a function of level of physical fitness. The more overweight/obese the person, the more likely they are to be insulin-resistant and at increased risk of cardiovascular disease, but substantial numbers of overweight/obese individuals remain insulin-sensitive, and not all insulin-resistant persons are obese.
Of greater clinical relevance is evidence that the metabolic benefit and decrease in risk of cardiovascular disease following weight loss occurs primarily in those overweight/obese individuals that are also insulin resistant. The relationship between insulin resistance and overall obesity, as assessed by measurement of body mass index, is essentially the same as the relationship between insulin action and abdominal obesity as quantified by determining waist circumference.
Finally, there appears to be a comparable relationship between insulin-mediated glucose disposal and amount of visceral fat, subcutaneous fat, and total fat as quantified by various imaging techniques, and the magnitude of these relationships is no greater than that between insulin action and simple measure of body mass index.
1. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP.Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obesity Research1997;5:542–8.
2.
2. Manson JE, Skerrett PJ, Greenland P, VanItallie TB.The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med2004;164:249–58.
3.
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2002;285:2486–97.
4.
4. Flegal KM, Graubard BI, Williamson DF, Gail MH.Excess death associated with underweight, overweight, and obesity. JAMA2005;293:1861–7.
5.
5. Gregg EW, Cheng YJ, Cadwell BL et al.Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA2005;293:1868–74.
6.
6. Olefsky JM, Reaven GM, Farquhar JW.Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest1974;53:64–76.
7.
7. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM.Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol1985;248:E286–E291.
8.
8. Ferrannini E, Natali A, Bell P, Cavallo-Perin, Lalic N, Mingrone G.Insulin resistance and hypersecretion in obesity. J Clin Invest1997;100:1166–73.
9.
9. Abbasi F, Brown BWB, Lamendola C, McLaughlin T, Reaven GM.Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol2002;40:937–43.
10.
10. Reaven GM.Role of insulin resistance in human disease. Diabetes1988;37:1595–607.
11.
11. Yip J, Facchini FS, Reaven GM.Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab1998;83:2773–6.
12.
12. Zavaroni I, Bonini L, Gasparini P et al.Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism1999;48:989–94.
13.
13. Facchini FS, Hua N, Abbasi F, Reaven GM.Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab2001;86:3574–8.
14.
14. Reaven G.The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am2004;33:283–303.
15.
15 Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM.Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care2000;23:171–5.
16.
16. Shen S-W, Reaven GM, Farquhar JW.Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest1970;49:2151–60.
17.
17. Greenfield MS, Doberne L, Kraemer FB, Tobey TA, Reaven GM.Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes1981;30:387–92.
18.
18. Pei D, Jones CNO, Bhargava R, Chen Y-DI, Reaven GM.Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia1994;37:843–5.
19.
19. Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven GM.Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes1983;32:408–11.
20.
20. Alberti KG, Zimmet PZ.Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med1998;15:539–53.
21.
21. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at:http://wwwidf.org/webdata/docs/IDF_Metabolicsyndrome_definition.pdf
22.
22. Ford ES, Mokdad AH, Giles WH.Trends in waist circumference among US adults. Obes Res2003;11:1223–31.
23.
23. Farin HM, Abbasi F, Reaven GM.Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. Metabolism2005;54:1323–8.
24.
24. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G.Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism2004;53:495–9.
25.
25. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G.Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med2003;139:802–09.
26.
26. McLaughlin T, Abbasi F, Lamendola C et al.Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation2002;106:2908–12.
27.
27. Abate N, Garg A, Peshock RM, Stray-Gunderson J, Grundy S.Relationships of generalized and regional adiposity to insulin sensitivity in man. J Clin Invest1995;96:88–98.
28.
28. Cefalu WT, Wang ZQ, Werbgel S et al.Contribution of visceral fat to the insulin resistance of aging. Metabolism1995;44:954–9.
29.
29. Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Veiiot R.Visceral adipose tissue impairs insulin secretion and sensitivity, but not energy expenditure in obesity. Metabolism1997;46:123–9.
31. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lbeovitz HE.Body composition, visceral fat, leptin and insulin resistance in Asian Indian Men. J Clin Endocrinol Metab1999;84:137–44.
32.
32. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH.Subdivisions of subcutaneous abdominal tissue and insulin resistance. Am J Physiol Endocrinol Metab2000;278:E941–E948.
33.
33. Sites CK, Calles-Escandon J, Brochu M, Butterfield M, Ashikaga T, Poehlman ET.Relation of regional fat distribution to insulin sensitivity in postmenopausal women. Fertil Sterl2000;73:61–5.
34.
34. Brochu M, Starling RD, Tchernof A, Mathews DE, Garcia-Rubi E, Poehlman ET.Visceral adipose tissue is an independent correlate of glucose disposal in older postmenopausal women. J Clin Endocrinol Metab2001;85:2378–84.
35.
35. Goran MI, Bergman RN, Gower BA.Influence of total vs. visceral fat on insulin action and secretion in African American and white children. Obes Res2001;9:423–31.
36.
36. Rendell M, Hulthen UL, Tornquist C, Groop L, Mattiason I.Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab2001;86:744–9.
37.
37. Purnell JQ, Kahn SE, Schwartz RS, Brunzell JD.Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with combined hyperlipidemia. Arterioscler Thromb Vasc Biol2001;21:567–72.
38.
38. Raji A, Seeley EW, Arky RA, Simonson DC.Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab2001;86:5366–71.
39.
39. Ross R, Aru J, Freman J, Hudson R, Janssen I.Abdominal obesity and insulin resistance in obese men. Am J Physiol Endocrinol Metab2002;282:E657–E663.
40.
40. Ross R, Freeman J, Hudson R, Janssen I.Abdominal obesity, muscle composition and insulin resistance in premenopausal women. J Clin Endocrinol Metab2002;87:5044–51.
41.
41. Cnop M, Landchild MJ, Vidal J et al.The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations. Diabetes2002;51:1005–15.
42.
42. Cruz ML, Bergman RN, Goran MI.Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care2002;25:1631–6.
43.
43. Gan SK, Krikeos AD, Poynten AM et al.Insulin action, regional fat, and myocyte lipid; altered relationships with increased adiposity. Obes Res2003;11:1295–305.
44.
44. Tulloch-Reid MK, Hanson RL, Sebring NG et al.Both subcutaneous and visceral adipose tissues correlate highly with insulin resistance in African Americans. Obes Res2004;12:1352–9.
45.
45. Rattarasarn C, Leelawattan R, Soonthornpun S, Setasuban W, Thamprasit A.Gender differences of regional abdominal fat distribution and their relationships with insulin sensitivity in healthy and glucose-intolerant Thais. J Clin Endocrinol Metab2004;89:6266–70.
46.
46. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R.Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal, subcutaneous, and visceral fat. Am J Clin Nutr2002;75:683–8.
47.
47. Kissebah AH, Vydelingum N, Murray R et al.Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab1982;54:254–60.
48.
48. Sparrow D, Borkan GA, Gerzof SG, Wisniewski C, Silbert CK.Relationship of fat distribution to glucose tolerance. Results of computed tomography in male participants of the Normative Aging Study. Diabetes1986;35:411–15.
50. Despres JP, Nadeau A, Tremblay A, Ferland M, Lupien PJ.Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes1989;38:304–09.
51.
51. Pouliot MC, Despres JP, Nadeau A et al.Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes1992;41:826–34.
52.
52. Kissebah AH, Krakower GR.Regional adiposity and morbidity. Physiological Reviews1994;74:761–811.
53.
53. Gautier JF, Milner MR, Elam E, Chen K, Ravussin E, Pratley RE.Visceral adipose tissue is not increased in Pima Indians compared with equally obese Caucasians and is not related to insulin action or secretion. Diabetologia1999;42:28–34.
54.
54. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC.Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity?. Diabetes Care2003;26:2556–61.
55.
55. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK.Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fat distribution. Diabetes1990;39:283–99.
56.
56. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB.Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr2005;81:555–63.
57.
57. Seidell JC, Cigolini M, Deslypere JP, Charzewska J, Ellsinger BM, Cruz A.Body fat distribution in relation to serum lipids and blood pressure in 38-year-old European men: the European fat distribution study. Atherosclerosis1991;86:251–60.
58.
58. Folsom AR, Li Y, Pao X et al.Body mass, fat distribution and cardiovascular risk factors in a lean population of south China. J Clin Epidemiol1994;47:173–81.
59.
59. Sakurai Y, Kono S, Shinchi K et al.Relation of waist-hip ratio to glucose tolerance, blood pressure, and serum lipids in middle-aged Japanese males. Int J Obes1995;19:632–7.
60.
60. Takami R, Takeda N, Hayashi M et al.Body fatness and fat distribution as predictors of metabolic abnormalities and early carotid atherosclerosis. Diabetes Care2001;24:1248–52.
